The overall survival of childhood leukaemia has increased dramatically over recent decades. With the increasing number of survivors, chemotherapy protocols are designed not only to improve cure rates but also to minimise long-term sequelae. Centralnervous-system-directed therapy given as intrathecal chemotherapy and/or cranial irradiation plays a crucial part in acute leukaemia treatment but can also result in adverse effects on the developing brain.
INTRODUCTION
The treatment of childhood leukaemia is one of the great success stories in paediatric oncology. Today patients with acute lymphoblastic leukaemia (ALL) have an 80% 5-year event-free survival, and those with acute myeloid leukaemia (AML) a 56% 5-year event-free survival. 1 2 As the numbers of long-term survivors of acute leukaemia rise, the long-term side effects and the quality of life of the survivors are drawn into greater focus. One of the most important concerns is the development of cognitive impairment. These neurodevelopmental sequelae may occur as a result of the leukaemia itself but are more often related to central nervous system (CNS)-directed therapy. The key to the successful treatment of meningeal leukaemia is its prevention. In the early 1970s, the introduction of CNS pre-emptive therapy as part of the treatment protocols for children with ALL dramatically decreased the occurrence of meningeal leukaemia, thus increasing the cure rate of childhood ALL (Table 1) .
METHODS
Studies of the neurocognitive effects of childhood ALL treatment were identifi ed through computerised literature searches of MEDLINE using combinations of the following search terms: neurocognitive, cognitive, intelligence, chemotherapy, radiation, long-term effects, sequelae, combined with leukaemia or cancer and child. In addition, reference lists from identifi ed articles and previous literature reviews were examined for additional studies. Only studies in the English language were included.
ALL and CNS therapy
The CNS is a sanctuary for lymphoblastic leukaemic blasts, and, protected by the blood-brain barrier, blasts in the CNS cannot be eradicated with systemic chemotherapy alone. Overt leukaemic involvement of the CNS at the time of diagnosis is an uncommon fi nding, occurring in fewer than 5% of patients. 3 Nonetheless, before the introduction of preventive CNS therapy, up to 70% of children with ALL who were in bone marrow remission relapsed in the CNS. 4 In the 1960s, the addition of craniospinal irradiation dramatically improved the overall survival. It was soon realised that the spinal component could be omitted. 5 The introduction of preventive 24 Gy cranial irradiation in conjunction with intrathecal chemotherapy was found to be highly effective and contributed signifi cantly to an increase in survival rates to more than 50% by the 1980s. However, this strategy was found to be associated with signifi cant toxicities including cognitive and developmental impairment, white matter changes, endocrinopathies and secondary malignancies. 6 The increasing number of long-term survivors has highlighted the need to address these longterm sequelae, and signifi cant efforts have been made to try to balance survival with the quality of that survival. Many studies have explored a reduction in, or elimination of, the use of cranial irradiation, substituting it with more intensive intrathecal and systemic administration of chemotherapy. Intrathecal chemotherapy delivers effective levels of cytotoxic agents directly to the CNS. It comprises either methotrexate (MTX) alone or triple intrathecal therapy with MTX, prednisolone and cytarabine. The combination of intrathecal chemotherapy with systemic high-dose MTX and leucovorin rescue is also an effective CNS-directed therapy. Initially, intrathecal and systemic chemotherapy was used in combination with cranial irradiation, but subsequently their regular use allowed a reduction in radiotherapy doses and ultimately its elimination for the majority of patients with ALL. In the UK, this was illustrated in the UKALL XI study with a risk-stratifi ed approach showing that intrathecal therapy is as effective as cranial radiation in preventing CNS relapse in the vast majority of patients. 7 Today the treatment of ALL is stratifi ed according to risk groups. Patients with a low risk for CNS relapse receive chemotherapy-only CNS-directed treatment (single agent MTX) without reducing the event-free or the overall survival. 3 7 The current UKALL 2003 protocol reserves cranial irradiation for the treatment of leukaemic involvement of the CNS at diagnosis. Children under the age of 2 years, even with CNS disease, do not receive any cranial irradiation but have more intensive intrathecal therapy. Neither the UK ALL 97/99 study nor ALL 2003, (the current study) has used routine cranial radiotherapy, yet both demonstrate a reduction in CNS relapse rate with improving event-free and overall survival. There is additional recent evidence that CNS-directed therapy can be omitted for all patients with newly diagnosed ALL. 8 It appears that the effects of systemic chemotherapy in reducing CNS relapse risk can be substantial.
The neurodevelopmental outcome for children and young people after ALL therapy may have a signifi cant impact on the quality of life in the short-and long term. The current strategy of combined intrathecal and systemic chemotherapy for CNS prophylaxis (omitting routine cranial radiotherapy) has reduced the adverse effects on neurocognitive development. 9 10 Nevertheless, despite the elimination of cranial irradiation, survivors of childhood ALL may have impairment of neurocognitive function. 11 12 Studies on neurocognitive outcome after ALL treatment show very heterogeneous results. This refl ects different methodological approaches to neurocognitive measures and the use of different chemotherapy protocols according to the national guidelines. Study designs to evaluate cognitive outcome include both longitudinal studies and a variety of crosssectional studies. The latter uses comparisons with standard norms or matched control groups of healthy friends, siblings or children suffering from chronic disease or non-CNS-treated cancers. Interestingly, the mean IQ value for healthy siblings of ALL patients has been found to be approximately 113. 13 Therefore, comparison with standard norms may underestimate cognitive impairment, thus emphasising the need for longitudinal studies or cross-sectional studies with an appropriate control group.
Cranial irradiation
Many reports have clearly documented the adverse effect of cranial irradiation on cognitive function. Children who received cranial irradiation display poorer performance on neuropsychological testing than non-irradiated patients. 14 A meta-analysis of 30 studies demonstrated that cranial irradiation is associated with declines in intelligence among survivors of childhood ALL. On average, this decrease was equivalent to 9-10 IQ points. 15 More detailed assessments have confi rmed that cranial irradiation and its combination with intrathecal MTX are associated with defi cits in visual-motor and fi ne-motor skills, verbal and spatial memory, coding, arithmetic achievement, attention, concentration and ability of sequencing and processing. [16] [17] [18] [19] There is evidence that the effect on intellectual functioning is more pronounced for non-verbal skills. 18 These fi ndings are refl ected in a poorer academic career 20 and a higher-than-average unemployment rate after cranial irradiation in childhood. 6 An association between dose of irradiation (36 Gy vs 24 Gy and 18 Gy, respectively) and IQ loss could be shown comparing patients with ALL and medulloblastoma. 21 However, it was not possible to demonstrate that the reduction in cranial irradiation from 24 Gy to 18 Gy in ALL protocols was of benefi t with respect to cognitive outcome. 22 23 The variable results reported may be infl uenced by differences in the intrathecal and systemic chemotherapy regimes used and methodological approaches.
It is broadly accepted that girls and younger children are more vulnerable to cranial irradiation. 15 21 24 Furthermore, the decline in intellectual functioning appears to be progressive, showing more impairment of cognitive function with increasing time since radiotherapy. 15 22 In summary, there is evidence that cognitive function after radiotherapy is infl uenced by dose of irradiation, age at irradiation, gender and time since irradiation, although it is anticipated that these effects will be seen less frequently in the future as the use of cranial irradiation in fi rst-line therapy for ALL has signifi cantly decreased.
Radiotherapy versus chemotherapy alone
When the neurocognitive outcome of radiotherapy and chemotherapy-only CNS regimens are directly compared, the evidence suggests a better outcome for those treated with chemotherapy alone. In Canada, the neurocognitive outcome 5 years post-treatment of 79 children with High Risk ALL was evaluated: they were treated with high-dose MTX or 18 Gy cranial irradiation. Those treated with radiotherapy performed more poorly on almost all of the neurodevelopmental measures affecting mainly memory and attention skills. 9 Campbell performed a meta-analysis of 28 studies of neurocognitive performance after ALL treatment with and without cranial irradiation. The performance of children who had received cranial irradiation was poorer for overall intellectual functioning than those receiving chemotherapy-only CNSdirected treatment. 10 
Chemotherapy alone
After the elimination of pre-emptive cranial irradiation from ALL treatment protocols, intrathecal and systemic chemotherapy has become the foundation of CNS-directed therapy. The results of studies evaluating the neurocognitive outcome of children after chemotherapy-only CNS-directed treatment are heterogeneous. Although most studies display good neurocognitive long-term outcome, 9 25 a recent review suggests generally modest potential late effects on specifi c areas of cognitive function in survivors who received chemotherapy alone. Processes of attention, speed of information processing, memory, verbal comprehension, visual-spatial skills and visual-motor functioning were mainly affected, while global intellectual function was found to be relatively preserved. 26 Recent longitudinal studies evaluating the long-term neurocognitive outcome provide little evidence for a decline in global IQ after treatment with chemotherapy alone. A Dutch prospective longitudinal study of 49 patients and 29 healthy siblings demonstrated no signifi cant differences in IQ or neuropsychological function apart from slight effects on complex fi ne-motor skills compared with healthy siblings 4.5 years after diagnosis. 25 One recent meta-analysis of 13 studies has suggested that ALL survivors with chemotherapy-only CNS-directed treatment score a lower full-scale IQ compared with controls. 11 However the study sizes were small and results highly variable. More commonly described are partial disturbances of neuropsychological performances. The specifi c areas affected include defi cits in academic achievement and specifi c cognitive skills such as processing speed, attention and memory. [27] [28] [29] [30] The academic achievement of ALL survivors in the long term seems to be generally average for reading and spelling with defi cits mainly affecting arithmetic performance. 12 28 Some diffi culties with specifi c cognitive skills such as attention, information-processing speed, visual-motor integration, fi ne motor skills and memory (particularly verbal memory) have been reported. 16 25 28 29 31-33 However, others describe normal memory function after chemotherapy-only CNS-directed therapy. 9 12 There is some evidence for a relationship between treatment intensity and adverse neurodevelopmental outcome. 34 Further risk factors for poor neurocognitive outcome after chemotherapy-only CNS-directed treatment are younger age and female gender. 11 35 36 Time since diagnosis or treatment does not appear to have a similar infl uence on neurocognitive functioning as observed following cranial irradiation, but follow-up in these studies still remains short.
Cognitive long-term effect of corticosteroids
Corticosteroids are highly effective in the treatment of ALL, and prednisolone has long been a standard component of treatment protocols. Dexamethasone has been shown to enhance lymphoblastic cytotoxicity with good penetration of CNS; it has replaced prednisolone in many recent treatment protocols. Children treated with dexamethasone have a signifi cantly reduced risk for isolated CNS-relapse and an improved event-free survival. 1 37 The side effects of long-term steroid treatment include myopathy, osteopenia, weight gain, hyperglycaemia, avascular necrosis and acute liver toxicity. Furthermore, children may experience adverse psychological effects and behavioural changes during treatment or on withdrawal of corticosteroids. 38 Concerns about late effects on cognitive function, particularly on memory, have also been expressed. A Dutch multicentre study on quality of life during ALL treatment including 41 children showed decreased cognitive functioning during the dexamethasone pulses compared with the non-dexamethasone treatment periods. 39 Early postnatal use of dexamethasone can have signifi cant adverse long-term effects on the developing brain affecting motor function, verbal skills and global intelligence, 40 which raises further theoretical concerns of its prolonged use in ALL where many patients present under the age of 4 years. Considering the better CNS penetration of dexamethasone, there are reports that dexamethasone may increase the risk for neurocognitive late effects in children treated for ALL compared with prednisolone. 41 However, more recent reports from ALL trials, randomising dexamethasone with prednisolone, could not demonstrate any differences on long-term neurocognitive functioning. 42 Other subgroups of patients with acute lymphoblastic leukaemia Infant ALL Infants diagnosed as having ALL are considered at a high risk for CNS disease. They are also extremely vulnerable to the side effects of cranial irradiation. Infants diagnosed before 2 years of age treated with cranial irradiation demonstrate signifi cant defi cits in overall intellectual function compared with cancer controls. 43 Currently, most treatment protocols do not specify cranial irradiation for infants or very young children, irrespective of CNS involvement at diagnosis. 44 45 The results of neuropsychological testing after chemotherapy-only CNS-directed therapy are encouraging. Thirty infants who were assessed on motor and cognitive indices after completion of ALL treatment on the CCG trial with chemotherapy-only CNS-directed therapy displayed mean scores within the average range for age-based population standards. 46 Patients with CNS relapse and following stem cell transplant
The survival rate after a isolated CNS relapse of ALL has improved, and long-term second event-free survival rates of 70% can be achieved. 47 48 Intensifi ed systemic chemotherapy and CNS-directed therapy are administered to patients with CNS relapse. In the 1980s, signifi cant IQ losses of 11-16 points 49 and signifi cant declines in academic achievement 50 were reported for such patients. The elimination of cranial irradiation in pre-emptive CNS treatment has reduced the neurocognitive long-term toxicity for patients with isolated CNS relapse. The reduced toxicity acquired in the initial treatment enables them to tolerate intensifi ed intrathecal chemotherapy and cranial irradiation for an isolated CNS relapse with fewer neurodevelopmental long-term sequelae. Patients are also older at the time of relapse and therefore less vulnerable to the impact of cranial irradiation on cognitive function. In 1995, a prospective study of 14 patients showed no overall group decline in full scale IQ and an average academic achievement after treatment of isolated CNS relapse, but, as one may expect, younger children displayed more neurocognitive impairment than those older at the time of diagnosis. 51 Intensifi ed treatment after relapse may include a stem cell transplant (SCT). Conditioning for SCT involves total body irradiation with 14 Gy and, in the case of CNS involvement, an additional cranial boost. Unfortunately, data on the neurocognitive outcome after SCT for leukaemia are limited. The few available prospective studies report little negative impact of SCT treatment on neurocognitive outcome. 52 Children and young people who have undergone SCT for either poor risk or more often recurrent leukaemia have often missed a considerable amount of schooling through their illness. The relative impact of the treatment compared with that of the loss of school and social contact is not known, but it is important that these issues be recognised and addressed for each individual patient.
Neuroradiological changes and their association with cognitive outcome in children with ALL
After treatment with cranial irradiation, approximately 50% of children have been reported to develop CNS changes detected by CT and MRI. 14 These changes include ventricular dilatation, atrophy, leucoencephalopathy, grey-matter abnormalities and intracerebral calcifi cations, some of which have been reported to be associated with a poorer performance on neuropsychological testing. 14 24 Radiological changes in survivors after chemotherapy alone are less pronounced than previously observed changes after radiotherapy. 14 32 Nevertheless, the extent of neuroimaging fi ndings vary in different studies ranging from white-matter abnormalities and atrophy without relation to neuropsychological outcome 32 53 54 to signifi cant widening of the sulci and ventricle and intracerebral calcifi cation. 14 Children with abnormalities identifi ed on imaging were generally younger at diagnosis of ALL. 54 Reduced cortical white-matter volume
was noted to be most prominent in the right prefrontal cortex. These white-matter volume differences have been associated with decreased performance in various domains of neurocognitive functioning, such as attention, visual-spatial skills, mental fl exibility and arithmetic achievements, when compared with children with no cancer history. 30 55 However, early acute white-matter abnormalities may be transient, 54 and their signifi cance for neurocognitive outcome is still unknown. In summary, current neuroimaging while on therapy does not provide enough information to predict a child's neurocognitive outcome.
Neurodevelopment late effects of AML therapy
The neurocognitive long-term outcome in children with AML has not been investigated widely. While, in ALL, the focus is on treatment-related long-term sequelae, in AML, cognitive sequelae are more likely to be caused by the leukaemia itself and its complications at presentation rather than by the treatment. During the initial phase of treatment, disturbed coagulation and leucostasis can lead to cerebrovascular events, which may affect long-term neurocognitive function signifi cantly.
In the UK, CNS-directed therapy for AML comprises two courses of 'triple' intrathecal chemotherapy (MTX, cytosine and hydrocortisone). Cranial irradiation is rarely used in the treatment protocols of childhood AML, and SCT is mainly reserved for the treatment of relapsed AML (Table 2) .
Long-term implications of CNS-directed therapy
A large epidemiological study in the USA-the Childhood Cancer Survivor Study-has been undertaken exploring outcomes for survivors of childhood cancer. Within this, the outcome for 4151 survivors of childhood ALL 25 years after diagnosis has demonstrated a lower socio-economic outcome for survivors who received cranial irradiation or treatment for relapse of the ALL. Adverse outcomes identifi ed were lower rates of marriage, college graduation and employment, and diffi culties obtaining health insurance. Conversely, survivors who did not receive cranial irradiation and never relapsed were not signifi cantly affected and reported comparable socio-economic status to siblings. 56 Supporting this is a study from St Judes in 856 patients, where an increased unemployment rate after cranial irradiation in ALL survivors compared with the general population is reported. Patients who received chemotherapy alone had an employment rate comparable with the general population. 6 In assessing outcomes for adolescents, the CCSS focused on the behaviour and social skills using parent-reported scores. Reports were available for 1345 survivors of leukaemia who were found to be approximately 1.5 times more likely than siblings to have symptoms of depression and anxiety, attention defi cit and antisocial behaviours. CNS-directed treatment including cranial irradiation and/or intrathecal MTX was shown to be a specifi c risk factor. 57 Although psychosocial outcome is not the main emphasis of this paper, it is important to understand the wider implications of any neurodevelopmental impairment for survivors of leukaemia. We have also not reported physical neurodevelopmental sequelae of treatment such as late vincristine toxicity (peripheral neuropathy), or sequelae of previous neurological events (eg, cerebrovascular accident), which may also have a signifi cant impact on the long-term outcome. To better understand the impact of the treatment for childhood leukaemia on neurocognitive outcome, continuous standardised monitoring is necessary as part of their longterm follow-up programme. These studies are important for our overall understanding of leukaemia, and the planning of future treatment protocols. They can also benefi t the individual child, as close longitudinal monitoring may detect early defi cits in IQ. These defi cits can be addressed with appropriate neurocognitive support designed for the special needs of survivors of CNS-directed treatment, so that any adverse impact on the child's quality of life can be minimised. 
